Serum Adropin Level Correlation with Blood Pressure: A case-control study

Marziye Vase; Amin Taheri; Mina Hemmati

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

Authors Guide Submit Manuscript

Serum Adropin Level Correlation with Blood Pressure: A case-control study

Authors:

Marziye Vase

¹,

Amin Taheri

^2,*,

Mina Hemmati

³

1Cardiology Department, Vali-e-Asr Hospital, Birjand University of Medical Sciences, Birjand, IR Iran

2Emergency Department, 22 Bahman Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran

3Biochemistry Department, School of Medicine, Birjand University of Medical Sciences, Birjand, IR Iran

International Cardiovascular Research Journal:Vol. 15, issue 3; e117243

Published online:Sep 15, 2021

Article type:Research Article

Received:Jun 19, 2021

Accepted:Aug 22, 2021

How to Cite:Marziye VaseAmin TaheriMina HemmatiSerum Adropin Level Correlation with Blood Pressure: A case-control study.15(3):e117243.

Abstract

Background: Hypertension is considered a fundamental health issue globally, and adropin is a vascular endothelial protection factor. The increasing prevalence of Hypertension (HTN); i.e., 20 - 50%, among adult populations in developed countries is one of the most common causes of Cardiovascular Diseases (CVDs). HTN is also the major modifiable risk factor for stroke (both ischemic and hemorrhagic). Adropin has the potential to protect the endothelium by increasing the expression of Nitric Oxide (NO) synthesis in the endothelium. Nonetheless, few studies have been conducted on the role of adropin in regulating blood pressure.

Objectives: The present study aimed to assess the adropin level and its relationship with blood pressure.

Methods: The present observational, case-control study was conducted on 40 hypertensive and 40 non-hypertensive patients. The patients’ data such as gender, age, years passed since HTN diagnosis, and blood pressure were recorded by the researcher. Then, adropin was measured by the Enzyme-Linked Immunosorbent Assay (ELISA) technique. After all, the significance of the relationship between the variables was statistically analyzed.

Results: The mean level of adropin was 5.44 ± 1.31 pg/mL in the study population. This measure was 4.91 pg/mL in the case group and 5.98 pg/mL in the control group, and the difference was statistically significant (P < 0.01). The results of ANCOVA showed that mean level of adropin was 1.19 units (24.5%) lower in the case group than in the control group after adjusting for age. The results also revealed a significant difference in the mean adropin level of the hypertensive patients based on the years passed since diagnosis (P < 0.01). Moreover, a negative correlation was observed between the adropin level and systolic blood pressure (rs = -0.273, n = 80, P = 0.014) and diastolic blood pressure (rs = -0.273, n = 80, P = 0.008). However, no significant correlation was found between age and adropin level (rs = -0.173, n = 80, P = 0.124).

Conclusions: Hypertensive patients had lower adropin levels in comparison to non-hypertensive ones. In addition, increase in the number of years passed since diagnosis was associated with decreased adropin levels.

Keywords

Enho Protein

Adropin Protein

Hypertension

Cardiovascular Disease

Fulltext

The full-text is available in pdf.

References

1.
The references are available in pdf.

comments